
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical Inc. stands to benefit from several potential upside drivers, notably faster growth in the spine market and stronger sales in its Enabling Technologies segment, which could enhance overall margins. The company is currently trading below historical valuation levels, while demonstrating impressive free cash flow growth with an 8% free cash flow yield, indicating a favorable risk/reward scenario. Despite recent revenue results slightly missing consensus expectations, strong profit potential remains, suggesting that the company may see continued financial improvement in the coming years.
Bears say
Globus Medical Inc faces several challenges that contribute to a negative outlook on its stock, including anticipated slower growth in the spine market and revenue dis-synergies from the recent NuVasive merger. The company's reliance on musculoskeletal solutions, which generates the majority of its revenue, may be hindered by factors such as lower-than-expected sales in its Enabling Technologies segment and increased competitive pressures following industry restructuring. Additionally, concerns regarding potential declines in operating margins and slower expansion into new market areas could further exacerbate financial performance issues.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares